News

Molecular Link Found Between Parkinson’s and Skin Cancer

Researchers have found a molecular link between Parkinson’s disease and melanoma, a type of skin cancer, in the form of protein clumps. Their study results were presented at the spring meeting of the American Chemical Society this week. A hallmark of Parkinson’s disease is the buildup of alpha-synuclein protein…

Neurons, Not Nearby Cells, Decide Dopamine Levels, Study Reports

Dopamine-releasing cells in the brain, much like most other hormone-producing cells, have a self-regulating feedback mechanism that controls their activity, researchers have discovered. That is, healthy nerve cells themselves determine how much dopamine will be released, the research team found, in contrast with the prevailing view that nearby cells “control”…

Health Canada Allows Start of DA01 Trial Testing Cell Therapy

BlueRock Therapeutics has received permission from Health Canada to start a Phase 1 clinical trial evaluating DA01, an investigational cell therapy that aims to restore neurons lost to Parkinson’s disease. This clearance comes three months after the U.S. Food and Drug Administration (FDA) accepted the company’s request…

Phase 2 Trial of Cognitive Treatment NYX-458 Resumes

Aptinyx‘s Phase 2 clinical trial evaluating its investigational oral compound NYX-458 for the treatment of cognitive impairment and mild dementia associated with Parkinson’s disease is resuming patient screening after a temporary pause due to the COVID-19 pandemic. Recruitment is underway at multiple locations in the United States.

Antibody-based Therapies May Trigger Brain Inflammation

New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…